Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin-like molecule 1 is a member of the C-type lectin domain-containing (CLEC) protein family, characterized by their carbohydrate-recognition domain, which typically binds ligands in a calcium-dependent manner. This group of surface receptors functions primarily in innate and adaptive immunity, mediating the recognition of pathogen- and damage-associated molecular patterns, and can modulate inflammation, cell-cell interactions, and immune signaling pathways. The broad family includes receptors like Dectin-1 (CLEC7A), MINCLE (CLEC4E), CLEC9A, and CLEC12A, each with distinct biological effects in immune cell signaling and homeostasis.
Modulation of immune cell activation Pattern recognition and signaling in response to ligands such as pathogens or damaged cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-type lectin-like molecule 1.